Recruiting

TMSPortable TMS Van for Treatment-Resistant Depression

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Left prefrontal Transcranial Magnetic Stimulation (TMS)

+ FDA cleared TMS for treating depression

Device
Who is being recruted

Anxiety Disorders+2

+ Behavior

+ Mental Disorders

From 22 to 80 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: May 2025
See protocol details

Summary

Principal SponsorMedical University of South Carolina
Study ContactMark S George, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 10, 2025

Actual date on which the first participant was enrolled.

This study explores a new way to deliver a type of treatment called transcranial magnetic stimulation (TMS) to people with depression that hasn't responded to other treatments. Researchers are creating a portable TMS unit inside a van to bring the treatment to different locations in South Carolina near Charleston. This approach could make TMS more accessible to many people who can't get treated at traditional locations. The goal is to learn how well this mobile method works and if it could be used more widely, especially in places like residential care facilities or remote clinics. Participants in the study are individuals with treatment-resistant depression living near selected clinics. They will receive TMS treatment inside the van, consisting of six sessions each day over two hours, for five days, within one or two weeks. Researchers will evaluate the effectiveness of the treatment using standard depression rating scales. Additionally, they will track the costs involved in providing this mobile service to see if it could be a feasible option for other healthcare providers in the future.

Official TitlePortable Transcranial Magnetic Stimulation (TMS) in a Van for Treatment-Resistant Depression
NCT06748209
Principal SponsorMedical University of South Carolina
Study ContactMark S George, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 22 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Anxiety DisordersBehaviorMental DisordersBehavioral SymptomsDepression

Criteria

5 inclusion criteria required to participate
Adult (22-80 years old)

Have treatment-resistant depression as defined by the e-Mini, and the antidepressant treatment history form (ATHF short).

Be able to read and communicate in English.

Able to provide their own consent.

Show More Criteria

4 exclusion criteria prevent from participating
Patients with unstable medical conditions that might make TMS unsafe. This includes current poorly controlled seizures.

Ferromagnetic metal in the head.

Pregnant.

Currently active substance abuse except tobacco.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

This will be FDA approved Left Prefrontal TMS for treating depression, we will be performing this within a VA, located at clinics throughout SC.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Medical Univerity of South Carolina

Charleston, United StatesOpen Medical Univerity of South Carolina in Google Maps
Recruiting
One Study Center